A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 and GW642444 as Monotherapies and Concurrently in Healthy Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Umeclidinium (Primary) ; Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
- 02 Feb 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from recruiting to completedas reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History